Abstract

<div>Abstract<p><b>Purpose:</b> To evaluate the antitumor efficacy of cetuximab in combination with LSN3074753, an analog of LY3009120 and pan-RAF inhibitor in 79 colorectal cancer patient-derived xenograft (PDX) models.</p><p><b>Experimental Design:</b> Seventy-nine well-characterized colorectal cancer PDX models were employed to conduct a single mouse per treatment group (<i>n</i> = 1) trial.</p><p><b>Results:</b> Consistent with clinical results, cetuximab was efficacious in wild-type <i>KRAS</i> and <i>BRAF</i> PDX models, with an overall response rate of 6.3% and disease control rate (DCR) of 20.3%. LSN3074753 was active in a small subset of PDX models that harbored <i>KRAS</i> or <i>BRAF</i> mutations. However, the combination treatment displayed the enhanced antitumor activity with DCR of 35.4%. Statistical analysis revealed that <i>BRAF</i> and <i>KRAS</i> mutations were the best predictors of the combinatorial activity and were significantly associated with synergistic effect with a <i>P</i> value of 0.01 compared with cetuximab alone. In 12 models with <i>BRAF</i> mutations, the combination therapy resulted in a DCR of 41.7%, whereas either monotherapy had a DCR of 8.3%. Among 44 <i>KRAS</i> mutation models, cetuximab or LSN3074753 monotherapy resulted in a DCR of 13.6% or 11.4%, respectively, and the combination therapy increased DCR to 34.1%. Molecular analysis suggests that EGFR activation is a potential feedback and resistant mechanism of pan-RAF inhibition.</p><p><b>Conclusions:</b> MAPK and EGFR pathway activations are two major molecular hallmarks of colorectal cancer. This mouse PDX trial recapitulated clinical results of cetuximab. Concurrent EGFR and RAF inhibition demonstrated synergistic antitumor activity for colorectal cancer PDX models with a <i>KRAS</i> or <i>BRAF</i> mutation. <i>Clin Cancer Res; 23(18); 5547–60. ©2017 AACR</i>.</p></div>

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.